Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 24 Carcinoma, Non-Small-Cell Lung 14 Squamous Cell Carcinoma of Head and Neck 13 Neoplasms 6 Lung Neoplasms 6 Colonic Neoplasms 6 Rectal Neoplasms 5 Pancreatic Neoplasms 5 Neoplasm Metastasis 5 Head and Neck Neoplasms 5 Mouth Neoplasms 4 Carcinoma 4 Laryngeal Neoplasms 3 Hypopharyngeal Neoplasms 3 Carcinoma, Squamous Cell 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Oropharyngeal Neoplasms 2 Endometrial Neoplasms 2 Thyroid Neoplasms 1 Skin Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neurofibromatosis 1 1 Neoplasms by Site 1 Neoplasm, Residual 1 Nasopharyngeal Carcinoma 1 Metastatic Solid Tumors 1 Melanoma 1 Lymphoid Interstitial Pneumonia 1 Locally Recurrent Skin Squamous Cell Carcinoma 1

Interventions

pembrolizumab 3 Pemetrexed 2 Oxaliplatin 2 Leucovorin 2 Fluorouracil 2 Carboplatin 2 trifluridine tipiracil drug combination 1 tislelizumab 1 sacituzumab govitecan 1 SYS6006 COVID-19 vaccine 1 Irinotecan 1 Drug Therapy 1 Docetaxel 1 Cetuximab 1 Bevacizumab 1 Antiemetics 1 ASP1570 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Solid Tumors × Cetuximab × 30 days × Clear all

NCT05067283 2026-05-26

KANDLELIT-001

Merck Sharp & Dohme LLC

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡